

# DRIVING CHANGE IN CANCER CARE.

It is a passionate commitment to providing innovations in oncology through a robust pipeline, which contains late stage assets, that fuels our drive to help cancer patients the world over. Our “patient first” core principle enables us to focus on bringing the right treatments to the right patients, no matter how big or small the need. From asset discovery, to creating alternative drug delivery methods, to following predictive biomarker strategies, GSK Oncology is breaking new ground with some of the most difficult to treat cancers.

Right now, we’re developing targeted therapies for solid and hematologic malignancies. Four

of our assets (pazopanib, Duodart/Avodart, Zunrisa/Rezonic and ofatumumab) are filed for regulatory approval, while several others have entered Phase III study. Our collective strengths in science, patient insight, and partnership models allow us to work with 160 cancer centers around the world to advance the care patients with cancer deserve.

*GSK is well represented at ASCO, with hundreds of employees attending and participating. Feel free to speak with any one of us about how GSK is driving change in cancer care, and what this might mean to your professional development.*

*Together we can make life better.*

[www.gsk.com/careers](http://www.gsk.com/careers)

GSK is proud to promote an open culture, encouraging people to be themselves and giving their ideas a chance to flourish. We are proud to be an equal opportunity employer.

